Dave brings 20 years of experience working with Fortune 500 and biotech executive teams on R&D portfolio management / strategy, product commercialization, and business development. While the span of his work includes all major therapeutic areas, particular areas of focus have included oncology, hematology, immunology, and pulmonology including orphan disease sub-segments.
Prior to joining Clearview, Dave led business development & strategy for Surface Oncology, a publicly traded immuno-oncology biotech. Before Surface, he had responsibility for worldwide commercial strategy for Bristol-Myers Squibb’s immuno-oncology portfolio which saw over 200 approvals across 50+ countries in ~3 years. Dave also brings extensive management consulting experience having served on the leadership team of The Frankel Group, now part of Huron Consulting, and in the life sciences practice of Deloitte Consulting.
Dave holds a B.S. in Computer Science and Business from Muhlenberg College and an MBA in Finance and Healthcare from the Wharton School of Business.
Debbi Amanti Belanger